Thalidomide-O-amido-PEG2-C2-NH2 TFA

Research use only, not for human use.

Thalidomide-O-amido-PEG2-C2-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology.

Thalidomide-O-amido-PEG2-C2-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology.(In Vitro):PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.

PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.

——

Cereblon Ligand-Linker Conjugates 10 TFA | E3 Ligase Ligand-Linker Conjugates 24 TFA

Others

Other Targets

H2 receptor

——

——

1957235-75-4

576.482

C23H27F3N4O10

>98% (HPLC)

In Vitro:? H2O : 150 mg/mL (260.20 mM)

OC(=O)C(F)(F)F.NCCOCCOCCNC(=O)COc1cccc2C(=O)N(C3CCC(=O)NC3=O)C(=O)c12

——

(-20℃)

With Ice Pack

≥ 2 years